Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects with Obesity or Overweight.

This research study is looking to recruit adults who are between the ages of 18 and 75, currently drinking alcohol, and are overweight or obese. The study will last approximately 32 weeks and will consist of approximately 14 visits. The purpose of the study is to explore whether the study medication, Pemvidutide, may help reduce alcohol use in individuals who meet these criteria . All participants will take part in regularly scheduled clinic visits and assessments. Everyone in the study will also receive standardized alcohol counseling through a computer-based program. All study-related activities, including the counseling and investigational product, is provided at no cost, and you will receive compensation for your time and travel.